We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug & Device Products
FDAnews Books Library
Events
Form 483s Database
Publications
Webinar Training Pass
eCFR and Guidances
Books
Clinical Products
Advertising
White Papers
Contact Us
About Us
COVID-19
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Kim Thomas Cruse
Kim Thomas Cruse
Products
PRODUCTS
IDT Biologika Gmbh
Kim Thomas Cruse
and
Victoria A. Wagoner
Price:
$117.00
View
Gilead Sciences, Inc.
Kim Thomas Cruse
and
Carl Lee
Price:
$117.00
View
Anchen Pharmaceuticals, Inc.
Kim Thomas Cruse
and
Carla J. Lundi
Price:
$117.00
View
Alliance Medical Products, Inc.
Teresa T. Cain
,
Kim Thomas Cruse
,
Carla J. Lundi
, and
Marcus F. Yambot
Price:
$117.00
View
Watson Laboratories, Inc.
Kim Thomas Cruse
,
John A. Gonzalez
, and
Carla J. Lundi
Price:
$117.00
View
Teva Parenteral Medicines, Inc.
Kim Thomas Cruse
,
Virgilio F. Facio
,
Jennifer M. Gogley
,
Carla J. Lundi
,
Joey V. Quitania
, and
Comyar Shoghi
Price:
$117.00
View
Upcoming Events
28
Jun
Effective Root Cause Analysis and CAPA Investigations for the Life Sciences
13
Jul
FDA Ad and Promo Enforcement Trends: Past, Present and Future
28
Jul
EU-MDR’s Growing Pains: Are You Current with the Latest Developments?
28
Jul
Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does
02
Aug
Medical Device Cybersecurity: Understand the Latest Developments
03
Aug
Pharmaceutical Process Validation: Best Practices for Success
Featured Products
FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485
Selecting and Implementing Electronic Document Management Systems in the EU
Featured Stories
Okami Medical’s LOBO-7 and LOBO-9 Vascular Occluders Cleared
FDA Puts Clinical Hold on Astellas Late-Onset Pompe Disease Clinical Trial
FDA Provides Update on GE Healthcare’s Recall of Its Carescape R860 Ventilators
Gilead Resubmits NDA for Lenacapavir Following Complete Response Letter
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
